捆绑白丝jk震动捧娇喘视频_国产一级不卡黄色av_久爱视频2019午夜视频_2020国产特级黄色自拍_亚洲熟妇AV日韩熟妇AV_国产精品欧美天美传媒_水蜜桃亚洲成人无码_歐美在線視頻網_日韩在线成人毛片_人妻激情中文字幕

 

 

 

Azithromycin is a macrolide antibiotic that is clinically suitable for infections caused by sensitive bacteria, including lower respiratory tract infections such as bronchitis and pneumonia; Skin and soft tissue infections; Acute otitis media; Upper respiratory tract infections such as sinusitis, pharyngitis, tonsillitis, etc; Simple genital infections caused by Chlamydia trachomatis.

 

 

 

Data shows that the sales revenue of azithromycin dry suspension in public medical institutions and urban pharmacies nationwide in 2024 was RMB 1.475 billion. According to the CDE website, other companies that have passed/are deemed to have passed the consistency evaluation for azithromycin dry suspension include Shiyao Group Ouyi Pharmaceutical Co., Ltd., Yichang Dongyangyang Changjiang Pharmaceutical Co., Ltd., Suzhou Dongrui Pharmaceutical Co., Ltd., and Hainan Puli Pharmaceutical Co., Ltd.

 

 

 

As of now, the company has invested approximately RMB 17.3725 million (unaudited) in research and development to carry out this project.

 

 

 

Sinopharm Modern stated that the consistency evaluation of the company's azithromycin dry suspension will be beneficial for the future market expansion and sales of the product. The above matters will not have a significant impact on the company's current operating performance.

 

 

 

Since 2025, multiple drugs of Sinopharm Modern have passed the consistency evaluation of generic drugs. In early June, Sinopharm Modern announced that the company and its wholly-owned subsidiary, Sinopharm Rongsheng Pharmaceutical Co., Ltd., had received the "Notice of Approval for Supplementary Drug Applications" approved by the National Medical Products Administration. Azithromycin tablets and dihydroxypropyl theophylline injection had passed the quality and efficacy consistency evaluation of generic drugs. Azithromycin tablets are suitable for infections caused by sensitive bacteria. In 2024, the sales revenue of public medical institutions and urban pharmacies in China was 685 million yuan. Dihydroxypropyl theophylline injection is suitable for treating bronchial asthma, etc. The sales revenue of public medical institutions in China in 2024 is 135 million yuan. This consistency evaluation is beneficial for product market expansion and sales.

 

 

 

On May 13th, Sinopharm Modern announced that its wholly-owned subsidiary, Sinopharm Rongsheng, has received the "Drug Supplementary Application Approval Notice" approved by the National Medical Products Administration, approving the quality and efficacy consistency evaluation of Amikacin Sulfate Injection as a generic drug. This drug is suitable for severe infections caused by sensitive gram-negative bacteria such as Pseudomonas aeruginosa, other Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus.

 

 

 

On April 28th, the company announced that the potassium chloride injection of its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has passed the quality and efficacy consistency evaluation of generic drugs. This drug is a commonly used medication to supplement potassium in the body, mainly used for the treatment and prevention of hypokalemia. The sales revenue of public medical institutions in China in 2023 is 619 million yuan. Guoyao Rongsheng has invested approximately 1.6354 million yuan in research and development. Evaluating is beneficial for product market expansion and sales, but there is uncertainty in the impact on performance.

 

 

 

Public information shows that Sinopharm Modern is a unified chemical pharmaceutical industry platform under Sinopharm Group, focusing on six major fields: "anti infection, cardiovascular, anesthesia and psychiatry, metabolism and endocrine, anti-tumor and immune regulation, and overall health".

 

 

 

In terms of performance, the 2024 annual report shows that the company's total operating revenue was 10.938 billion yuan. The net profit attributable to the parent company was 1.084 billion yuan, an increase of 392 million yuan compared to the same reporting period last year, achieving a three-year continuous increase and a 56.62% increase compared to the same period last year.